Filing Summary
Halozyme Therapeutics, Inc. filed this Form 8-K on September 30, 2026, reporting an event dated September 28, 2026. The filing concerns a board appointment; it does not report operating or financial results.
Board Appointment
- James Daly was elected to the Board of Directors on September 28, 2026, for a term ending at the 2029 annual meeting of stockholders.
- He was not initially assigned to a Board committee.
- Mr. Daly will receive compensation under the company’s non-employee director compensation program, which currently includes cash retainers, restricted stock and stock options. The filing refers to the 2026 proxy statement for program details.
- The company reported no arrangements or understandings related to his election and no related-person transactions with Mr. Daly.
Financial Information and Outlook
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, guidance or outlook figures. It discloses no financial contingencies or unusual items.
Key Facts to Verify
- Review the 2026 proxy statement for the director compensation program’s terms and award details.
- Confirm any subsequent Board committee assignments or other updates concerning Mr. Daly.